Truseltiq

Chemical Nameinfigratinib
Dosage FormCapsule (oral; 25 mg, 100 mg)
Drug ClassKinase Inhibitors
SystemDigestive
CompanyQED Therapeutics Inc.
Approval Year2021

Indication

  • For the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement as detected by an FDA-approved test.
Last updated on 10/4/2021

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Truseltiq (infigratinib) Prescribing Information2021QED Therapeutics Inc., Brisbane, CA